吡咯并[2,1-b]喹唑啉,1,2,3,9-四氢-2-甲基- | 97489-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 吡咯并[2,1-b]喹唑啉,1,2,3,9-四氢-2-甲基-
• 中文别名: [1,3]噻唑并[5,4-f]喹唑啉
• 英文名称: [1,3]Thiazolo[5,4-F]quinazoline
• CAS: 97489-87-7
• 化学式: C₉H₅N₃S
• 分子量: 187.22
• InChiKey: VZMHMNIMQLDBOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS<br/>[FR] PIPERAZINE BENZOTHIAZOLES UTILISES COMME AGENTS POUR LE TRAITEMENT DE TROUBLES ISCHEMIQUES CEREBRAUX OU DE TROUBLES DU SYSTEME NERVEUX CENTRAL (SNC)
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003091249A1

  公开（公告）日：2003-11-06

  The present invention is related to piperazine benzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation.

  本发明涉及哌嗪苯并噻唑衍生物，特别是用于治疗和/或预防脑缺血性疾病或中枢神经系统疾病。本发明还涉及它们的制备方法。
• Benzothiazole Formulations and Use Thereof
  申请人：Esposito Pierandrea

  公开号：US20080051397A1

  公开（公告）日：2008-02-28

  The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.

  本发明涉及含有苯并噻唑衍生物的大聚乙二醇甘油酯制剂。具体地，本发明涉及苯并噻唑硬脂酰大聚乙二醇制剂，其制备方法和用途。
• [EN] DYRK1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE DYRK1 ET LEURS UTILISATIONS
  申请人：EXONHIT SA

  公开号：WO2013026806A1

  公开（公告）日：2013-02-28

  The present invention relates to novel thiazolo[5,4-ƒ]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the invention relates to DYRK1A and/or DYRK1B inhibitors and to methods for preparing such compounds.

  本发明涉及新型噻唑并[5,4-ƒ]喹噁唑化合物及其在改善、治疗或控制唐氏综合征或早期阿尔茨海默病或改善、治疗或控制癌症，特别是固体肿瘤方面有用的方法。更具体地说，该发明涉及DYRK1A和/或DYRK1B抑制剂以及制备这类化合物的方法。
• [EN] KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE KINASE, COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2021263129A1

  公开（公告）日：2021-12-30

  Disclosed herein are kinase inhibitor compounds having the structure (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, L, Q, and Y are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

  本文披露了具有结构（I）或其立体异构体、药学上可接受的盐、氧化物或溶剂的激酶抑制剂化合物，其中R1、R2、X、L、Q和Y如本文所定义。还披露了含有激酶抑制剂化合物的组合物，抑制细胞中激酶活性的方法，增加胰岛β细胞群体中细胞增殖的方法，治疗因胰岛素分泌不足引起的疾病的方法，以及治疗神经系统疾病的方法。
• Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders
  申请人：Gaillard Pascale

  公开号：US20050261304A1

  公开（公告）日：2005-11-24

  The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation.

  本发明涉及哌嗪苯并噻唑衍生物，特别是用于治疗和/或预防脑缺血性疾病或中枢神经系统疾病。本发明还涉及其制备方法。